Evaluation of the effectiveness of Ahmed's valve implantation adding mitomicin C in patients with refractory glaucoma after one year of follow-up

Archivos de la Sociedad Espanola de Oftalmologia Pub Date : 2025-09-01 DOI:10.1016/j.oftale.2025.07.008

O. Teherán , C. Parra , E. Ramos , M. Ochoa , W. Escobar

{"title":"Evaluation of the effectiveness of Ahmed's valve implantation adding mitomicin C in patients with refractory glaucoma after one year of follow-up","authors":"O. Teherán , C. Parra , E. Ramos , M. Ochoa , W. Escobar","doi":"10.1016/j.oftale.2025.07.008","DOIUrl":null,"url":null,"abstract":"<div><h3>Purpose</h3><div>To evaluate the effectiveness and safety of mitomycin C (MMC) use when implanting Ahmed valve in patients with refractory glaucoma.</div></div><div><h3>Methods</h3><div>Cohort study involving 34 patients divided into two groups of 17 patients each: Group 1 (MMC use) and Group 2 (no MMC use), with a one-year follow-up. Complete success was defined as intraocular pressure (IOP) between 6−18 mmHg without the use of antiglaucoma medications; qualified success referred to the same IOP range but associated with antiglaucoma medications, while failure was characterized by IOP outside this range, severe complications or reintervention.</div></div><div><h3>Results</h3><div>The overall success rate in Group 1 was 88.2%, and in Group 2, 94.2%. There was an average reduction in IOP of 18.0-± 11.5 mmHg in Group 1 and 11.3 ± 5.0 mmHg in Group 2. The hypertensive phase occurred in 17.6% of the participants in the first group and the second, 70.6%.</div></div><div><h3>Conclusions</h3><div>The use of MMC decreases the hypertensive phase observed in Ahmed valve implant surgery, thereby achieving better IOP control.</div></div>","PeriodicalId":93886,"journal":{"name":"Archivos de la Sociedad Espanola de Oftalmologia","volume":"100 9","pages":"Pages 521-527"},"PeriodicalIF":0.0000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Archivos de la Sociedad Espanola de Oftalmologia","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2173579425001240","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose

To evaluate the effectiveness and safety of mitomycin C (MMC) use when implanting Ahmed valve in patients with refractory glaucoma.

Methods

Cohort study involving 34 patients divided into two groups of 17 patients each: Group 1 (MMC use) and Group 2 (no MMC use), with a one-year follow-up. Complete success was defined as intraocular pressure (IOP) between 6−18 mmHg without the use of antiglaucoma medications; qualified success referred to the same IOP range but associated with antiglaucoma medications, while failure was characterized by IOP outside this range, severe complications or reintervention.

Results

The overall success rate in Group 1 was 88.2%, and in Group 2, 94.2%. There was an average reduction in IOP of 18.0-± 11.5 mmHg in Group 1 and 11.3 ± 5.0 mmHg in Group 2. The hypertensive phase occurred in 17.6% of the participants in the first group and the second, 70.6%.

Conclusions

The use of MMC decreases the hypertensive phase observed in Ahmed valve implant surgery, thereby achieving better IOP control.

查看原文本刊更多论文

加入肌霉素c的艾哈迈德瓣膜植入物在难治性青光眼患者随访一年的疗效评价。

目的：评价丝裂霉素C （MMC）在难治性青光眼患者艾哈迈德瓣膜植入术中的有效性和安全性。方法：将34例患者分为两组，每组17例：1组（使用MMC）和2组（未使用MMC），随访1年。在没有使用抗青光眼药物的情况下，眼内压（IOP）在6-18 mmHg之间是完全成功的定义；合格的成功是指相同的IOP范围，但与抗青光眼药物相关，而失败的特征是IOP超出该范围，严重的并发症或再干预。结果：1组总成功率为88.2%，2组总成功率为94.2%。组1平均眼压降低18.0±11.5 mmHg，组2平均眼压降低11.3±5.0 mmHg。第一组和第二组高血压期分别为17.6%和70.6%。结论：MMC的使用减少了Ahmed瓣膜置换术中观察到的高血压期，从而达到更好的IOP控制。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Archivos de la Sociedad Espanola de Oftalmologia

自引率

0.00%

发文量